CDEK
← All drugs Report issue

omigapil

Small moleculeexperimental

Omigapil is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit, but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD). — Wikipedia

Clinical trial activity

5 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2002 (NCT00407212)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C#CCN(C)CC1=Cc2ccccc2Oc2ccccc21
Mol. weight
275.35 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cgp 3466
  • cgp-3466
  • cgp3466b
  • cgp 3466b
  • cgp-3466b
  • dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine
  • omigapil
  • omigapil
  • omigapil
  • omigapil
  • omigapil
  • tch346
  • tch346
  • tch346
  • tch 346
  • tch-346

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01805024Phase 1Dec 1, 2014Santhera
NCT00230074Phase 2Nov 1, 2004Novartis
NCT00072709Phase 2Sep 1, 2003Novartis
NCT00036413Phase 2Jan 1, 2002Novartis
NCT00407212Phase 1/Phase 2 (Phase 2)Jan 1, 2002Novartis
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit4412002
SantheraFor profit1112014
2 organizations
Page 1 / 1